The burgeoning popularity of tirzepatide , initially for metabolic conditions, is creating significant attention within the United Kingdom , prompting a notable shift in peptide trends. Access these treatments remains a complex landscape, with public healthcare system coverage currently limited and specialist practices offering therapy at a substan